Grant Recipients | Aplastic Anemia & MDS International Foundation Return to top.

Grant Recipients

For nearly 30 years, AAMDSIF has provided research grants totaling in excess of $5 million to an international group of more than 90 researchers to help advance the understanding and treatment of aplastic anemia, myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH).

The two-year grants have helped bring forth new insights into the causes and therapeutic approaches for these diseases. These grantee profiles present the grantees by year the awards were granted, and a summary of their grant-funded research projects.

View a single grant year.

Grant Year: 2022

David Beck, MD, PhD

Harold Spielberg Research Fund

Acquired bone marrow failure syndromes, such as myelodysplastic syndrome (MDS), are frequently caused by genetic mutations. Both the underlying mechanism and prognosis of MDS have been attributed to specific driver gene mutations, and genetic classification systems have led to improved clinical outcomes. Bone marrow failure, and MDS have been linked to autoimmune diseases although the clinical relevance of these associations has not been well defined. We identified an acquired mutation in the gene UBA1 that occurs in the earliest progenitors in the bone marrow, and leads to common inflammatory rheumatic and hematologic diseases such as rheumatoid arthritis and myelodysplastic syndrome. Patients with mutations in UBA1 have VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic)...

Sushant Kumar, PhD

PNH Research and Support Foundation

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare blood disease in which blood cells are destroyed, leading to anemia, fatigue, and increased risk of blood clots. While several effective therapies can prevent the destruction of PNH red blood cells by blocking abnormal activation of a part of the immune system called “complement”, these treatments are life-long, extremely costly and do not lead to cure. In many places around the world, access to PNH treatments is limited. The main barrier to developing curative therapies for PNH has been a poor understanding of why PNH patients develop large outgrowths (“clones”) of PNH cells. Interestingly, most healthy individuals also harbor a few, very rare, isolated PNH cells, but these do not outgrow normal cells and do not turn into PNH clones,...

Grant Year: 2021

Salima Benbarche, PhD

Harold Spielberg Research Fund

We discovered a way to express a gene or protein of interest in cancer cells, but not healthy normal cells. Specifically, we created synthetic (not occurring in nature) introns that we can introduce into any gene of interest, such as a “killer gene,” such that the encoded protein is produced in cancer cells carrying a defined, cancer-causing mutation, but not produced in healthy normal cells that do not carry that specific mutation. These types of cancer-causing mutations are mainly identified in patients with myelodysplastic syndromes, a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells. We believe that these synthetic introns will enable the development of new cancer therapeutics that are highly specific to cancer cells while...

Sushree Sahoo, PhD

Emily Kass Research Fund

Myelodysplastic syndrome (MDS) in children is a rare group of disorders in which blood-making stem cells in the bone marrow (BM) fail to work properly. As a result, patients develop low blood counts and have increased risk to develop leukemia with cancerous cells, referred to as blasts, also called refractory cytopenia of childhood (RCC). Although RCC is the most common category, we do not fully understand its molecular basis (gene and chromosome changes associated with the disease). Some patients with RCC have empty BM which might be mistaken for aplastic anemia, while others have acquired changes that predispose them to more advanced MDS and leukemia. Therefore, it is often difficult to tell apart RCC from other blood disorders such as inherited marrow failure or acquired aplastic...

Grant Year: 2020

Valentina Giudice, MD

Amy Gaynor Research Fund

Circulating low-density granulocytes (LDGs) are a subgroup of neutrophils with immunoregulatory functions which can spontaneously release extracellular web-like structures (NETs) and cytokines sustaining T cell responses and dendritic cell activation. We hypothesize that LDGs and NETs might be impaired in functions and frequency during myelodysplastic syndromes (MDS) and acquired aplastic anemia (AA) and might contribute to the suppression of hematopoietic stem cell proliferation and differentiation. We aim at investigating over a 12 month period the frequency and functions of LDGs and NET formation and composition in MDS and AA at diagnosis and during treatments. Moreover, the number of LDGs and NET levels will be correlate to other markers of inflammation and genomic alterations. This...

Audrey Lasry, PhD

Harold Spielberg Research Fund

Myelodysplastic syndrome (MDS) is a pre-cancerous disease of the blood, which progresses to the more aggressive acute myeloid leukemia (AML) in approximately 30% of cases. MDS currently affects about 60,000 people in the US, and about 10,000 new cases are diagnosed each year. Life expectancy for MDS patients ranges from 5 months to 3 years, yet therapeutic options for MDS patients are limited. In recent years, advances in understanding of the immune system have led to a major breakthrough in cancer therapy, with the development of immunotherapy drugs that target the immune system rather than the cancer cells. These drugs are effective in many types of cancer, and have revolutionized treatment for cancers that were often considered untreatable in the past. The effectiveness of...

Grant Year: 2019

Jill de Jong, MD, PhD

Julia Malsin Research Fund

Aplastic anemia is a rare but serious blood disorder that occurs when the body’s bone marrow cannot produce enough healthy blood cells to function properly. Aplastic anemia can be classified as moderate, severe or very severe, depending on stability of blood cell count and other symptoms. Most cases of aplastic anemia are idiopathic, meaning the underlying cause is unknown. Aplastic anemia can be due to inherited (genetic) causes in a minority of cases. Although many patients with genetic causes of aplastic anemia will present with more moderate blood counts initially and may have a family history of blood disorders and other physical findings associated with these genetic disorders, some patients may not have any of these findings. It is not currently known how many patients who present...

Christin DeStefano, MD

The National Academy of Sciences Engineering and Medicine’s (NASEM) Veterans and Agent Orange (AO) Committees have been performing biennial reviews of the literature examining the relationship between AO exposure and the risk for adverse health outcomes since 1996. In 2018, the committee concluded there are sufficient data to associate AO exposure with an increased risk of Hodgkin and non-Hodgkin lymphoma, chronic lymphocytic leukemia, monoclonal gammopathy of unknown significance, and hypertension. In 22 years of follow up, there is only one paper addressing myelodysplastic syndrome (MDS) and none addressing aplastic anemia (AA) or myeloproliferative neoplasms (MPNs). The under representation is likely multifactorial, but low incidence is likely a major factor. This conundrum, lack of...

Grant Year: 2018

Eunice Sindhuvi Edison, PhD

Liviya Anderson Research Fund

Androgens have been used alone or in combination with other immunosuppressive therapy in aplastic anemia with inconsistent responses being reported. However, the exact mechanism of action of androgens is not known. Recent studies have shown that it tends to protect from telomere shortening in haematopoietic tissues by increasing telomerase activity. In addition, androgens exert various biological effects on both haematopoietic cells and stromal cells. Androgen receptors are found to be expressed on stromal cells, macrophages, endothelial cells, myeloblasts, myelocytes, neutrophils, and megakaryocytes. Androgens also have a suppressive effect on the immune system. Shortened telomeres in aplastic anemia were initially attributed to stress factors but was later recognized that telomere...

Valeria Visconte, PhD

Patricia and Vincent Geczik Legacy Fund

Paroxysmal nocturnal hemoglobinuria (PNH) is a stem cell disorder caused by a mutation in a gene called phosphatidylinositol glycan anchor biosynthesis class A gene (PIGA). PIGA produces a protein important in the formation of a group of proteins called glycophosphatidylinositol anchored proteins (GPI-AP). GPI-AP are attached to the cell membrane via a small anchor. Among them CD59 and CD55 are major targets for therapy. Due to PIGA mutation, PNH cells fail to synthesize a correct anchor and thereby lack of proper GPI-AP. To date, the drug developments for PNH have focused on supportive therapies to improve hemoglobin levels due to hemolysis or prevent thrombotic complications. Most successful to date were complement blockers designed for alleviation of hemolysis due to deficiency in...
Share with